

29 September 2015 EMA/HMPC/143658/2015 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Polygonum aviculare* L., herba

Draft

| Discussion in Working Party on European Union monographs and list | March 2015 |
|--|-------------------|
| (MLWP) | May 2015 |
| | July 2015 |
| Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation | 29 September 2015 |
| Start of public consultation | 19 October 2015 |
| End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu > | 15 January 2016 |
| Rediscussion in MLWP | |
| Adoption by HMPC | |

| Keywords | Herbal medicinal products; HMPC; European Union herbal monographs; |
|----------|--|
| | traditional use; Polygonum aviculare L., herba; Polygoni avicularis herba; |
| | Knotgrass herb |

| BG (bulgarski): Пача трева, стрък | IT (italiano): Centinodio (Correggiola) parti aeree |
|---|---|
| CS (čeština): nať rdesna ptačího | fiorite LT (lietuvių kalba): Takažolių žolė |
| DA (dansk): Vejpileurt | LV (latviešu valoda): Maura sūrenes laksts |
| DE (Deutsch): Vogelknöterichkraut | MT (Malti): ħaxixa tal-Lewża Tar-Raba' |
| EL (elliniká): Πόα πολυγόνου του άρρενος | NL (Nederlands): Gewoon varkensgras, kruid |
| EN (english): Knotgrass herb | PL (polski): Ziele rdestu ptasiego |
| ES (español): Centinodia, partes aéreas de | PT (português): Corriola-bastarda, partes aéreas |
| ET (eesti keel): linnurohuürt | RO (română): Iarbă de troscot |
| FI (suomi): pihatatar, verso | SK (slovenčina): Vňať stavikrva vtáčieho |
| FR (français): Renouée des oiseaux (parties | SL (slovenščina): zel ptičje dresni |
| aériennes de) | SV (svenska): Trampgräs, ört |
| HR (hrvatski): oputinova zelen | IS (íslenska): |
| HU (magyar): madárkeserűfű virágos hajtás | NO (norsk): Tungress |



European Union herbal monograph on *Polygonum aviculare* L., herba

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition 1, 2

| Well-established use | Traditional use |
|----------------------|--|
| | With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended |
| | Polygonum aviculare L., herba (Knotgrass herb) |
| | i) Herbal substance |
| | Not applicable. |
| | ii) Herbal preparations |
| | Comminuted herbal substance |

3. Pharmaceutical form

| Well-established use | Traditional use |
|----------------------|---|
| | Comminuted herbal substance as herbal tea for oral use. |
| | Comminuted herbal substance for decoction preparation for oromucosal use. |
| | The pharmaceutical form should be described by the European Pharmacopoeia full standard term. |

4. Clinical particulars

4.1. Therapeutic indications

| Well-established use | Traditional use |
|----------------------|--|
| | Indication 1) |
| | Traditional herbal medicinal product used for the relief of symptoms of common cold. |

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

The material complies with the Ph. Eur. monograph (ref.: 1885)

| Well-established use | Traditional use |
|----------------------|--|
| | Indication 2) |
| | Traditional herbal medicinal product used for symptomatic treatment of minor inflammations in the mouth or the throat. |
| | Indication 3) |
| | Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints. |
| | The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. |

4.2. Posology and method of administration³

| Well-established use | Traditional use |
|----------------------|---|
| | Posology |
| | Adolescents, adults and elderly |
| | Indication 1) |
| | Single dose Herbal tea: 1.5 - 2 g of the comminuted herbal substance in 150 ml of boiling water as a herbal infusion 3 - 4 times daily. Daily dose: 4.5 - 8 g |
| | Indication 2) |
| | Single dose Comminuted herbal substance for decoction preparation for oromucosal use: 1.5 g of the comminuted herbal substance in 200 - 250 ml of water 4 - 5 times daily for gargling of the mouth and throat. |
| | Daily dose: 6 - 7.5 g |
| | |
| | |
| | |
| | |

 $^{^3}$ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

| Well-established use | Traditional use |
|----------------------|--|
| | Indication 3) |
| | Single dose Herbal tea: 3 g of the comminuted herbal substance in 200 ml of water as a decoction 2 times daily. |
| | Daily dose: 6 g |
| | Indication 1), 2) and 3) |
| | The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | Duration of use |
| | Indication 1) and 2) |
| | If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | Indication 3) |
| | If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | Method of administration |
| | Indication 1) and 3) |
| | Oral use. |
| | Indication 2) |
| | Oromucosal use. |

4.3. Contraindications

| Well-established use | Traditional use |
|----------------------|--|
| | Hypersensitivity to the active substance(s). Indication 3) |
| | Conditions where reduced fluid intake is recommended (e.g. severe cardiac diseases). |

4.4. Special warnings and precautions for use

| Well-established use | Traditional use |
|----------------------|---|
| | Indication 1), 2) and 3) |
| | The use in children under 12 years of age has not been established due to lack of adequate data. |
| | Indication 1), 2) |
| | If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 3) |
| | If complaints of symptoms such as fever, dysuria, spasms or blood in the urine occur during the use of the medicinal product, a doctor or a qualified health care professional should be consulted. |
| | To ensure an increase of the amount of urine, adequate fluid intake is required during treatment. |

4.5. Interactions with other medicinal products and other forms of interaction

| Well-established use | Traditional use |
|----------------------|-----------------|
| | None reported. |

4.6. Fertility, pregnancy and lactation

| Well-established use | Traditional use |
|----------------------|---|
| | Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. |
| | No fertility data available. |

4.7. Effects on ability to drive and use machines

| Well-established use | Traditional use |
|----------------------|--|
| | No studies on the effect on the ability to drive and use machines have been performed. |

4.8. Undesirable effects

| Well-established use | Traditional use |
|----------------------|---|
| | None known. |
| | If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. |

4.9. Overdose

| Well-established use | Traditional use |
|----------------------|--|
| | No case of overdose has been reported. |

5. Pharmacological properties

5.1. Pharmacodynamic properties

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |

5.2. Pharmacokinetic properties

| Well-established use | Traditional use |
|----------------------|---|
| | Not required as per Article 16c(1)(a)(iii) of |
| | Directive 2001/83/EC as amended. |

5.3. Preclinical safety data

| Well-established use | Traditional use |
|----------------------|---|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. |

6. Pharmaceutical particulars

| Well-established use | Traditional use |
|----------------------|-----------------|
| | Not applicable. |

7. Date of compilation/last revision

29 September 2015